Pharmacotherapy of Type 1 Diabetes in Children

April 17, 2019 (Noon–1:15 p.m. ET)


Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), Best Pharmaceuticals for Children Act, NICHD




Diabetes is one of the most common chronic diseases of childhood and can lead to short- and long-term complications. Its global rate has been increasing significantly for several decades. While managing diabetes continuously and carefully and improving glycemic control have been established as mainstays of therapy, treatment outcomes have been far from satisfactory. Eda Cengiz, M.D., M.H.S., FAAP, will discuss the management of type 1 diabetes in children, with a special focus on challenges and opportunities of diabetes pharmacotherapy.

In her presentation, Dr. Cengiz will:

  • Summarize the status of diabetes management in children with type 1 diabetes and basic principles of diabetes pharmacotherapy in the pediatric population.
  • Discuss challenges and unmet needs of diabetes pharmacotherapy in children with type 1 diabetes and opportunities to address the unmet needs.
  • Review recent advances in pediatric diabetes pharmacotherapy and the effect of diabetes technology in improving treatment of diabetes.

Dr. Cengiz is associate professor of pediatrics at Yale University School of Medicine and director of Yale’s Insulin Pharmacokinetics and Pharmacodynamics Research Study Center—the only center in the world to conduct insulin action studies in children and adolescents with type 1 diabetes.


George Giacoia, OPPTB, NICHD
Phone: 301–496–5589

Please note: Views expressed during NICHD-sponsored events do not necessarily reflect the opinions or the official positions of NICHD, NIH, or HHS.
top of pageBACK TO TOP